Erysipelas medical therapy
|
Erysipelas Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Erysipelas medical therapy On the Web |
|
American Roentgen Ray Society Images of Erysipelas medical therapy |
|
Risk calculators and risk factors for Erysipelas medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
The mainstay of therapy for erysipelas involves antimicrobial therapy with either Penicillins, Erythromycin, Ceftriaxone, or Cefazolin.
Medical Therapy
Antimicrobial Regimen
- Erysipelas[1]
- 1. Adults
- Preferred regimen (1): Penicillin 500 mg PO qid
- Preferred regimen (2): Amoxicillin 500 mg PO qid
- Preferred regimen (3): Erythromycin 250 mg PO qid
- Preferred regimen (4): Ceftriaxone 1 g IV q24h
- Preferred regimen (5): Cefazolin 1 to 2 g IV q8h
- 2. Pediatrics
- Preferred regimen (1): Penicillin 25 to 50 mg/kg/day PO tid or qid
- Preferred regimen (2): Amoxicillin 25 to 50 mg/kg/day PO tid
- Preferred regimen (3): Erythromycin 30 to 50 mg/kg/day PO bid to qid
- Preferred regimen (4): Ceftriaxone 50 to 75 mg/kg/day IV q12-24h
- Preferred regimen (5): Cefazolin 100 mg/kg/day IV q8h
- Facial erysipelas[2]
- 1. Causative pathogens
- Staphylococcus aureus
- Streptococcus spp. (Group A, B, C, & G)
- Enterobacteriaceae
- Clostridium spp.
- 2. Empiric antimicrobial therapy
- Preferred regimen: Vancomycin 1 g IV q12h
- Alternative regimen: Daptomycin 4 mg/kg IV q24h OR Linezolid 600 mg IV q12h
References
- ↑ Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL; et al. (2014). "Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America". Clin Infect Dis. 59 (2): 147–59. doi:10.1093/cid/ciu296. PMID 24947530.
- ↑ Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.